Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HXN-1002
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Recipient : Earendil Labs
Deal Size : $1,845.0 million
Deal Type : Licensing Agreement
Earendil Labs Licenses Bispecific Antibodies for Autoimmune use from Sanofi
Details : Under the licensing agreement, Sanofi will obtain exclusive worldwide rights to antibody, HXN-1002. It is designed to provide a treatment option for patients with ulcerative colitis.
Product Name : HXN-1002
Product Type : Antibody
Upfront Cash : $125.0 million
April 17, 2025
Lead Product(s) : HXN-1002
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Recipient : Earendil Labs
Deal Size : $1,845.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent (dupilumab), a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways, shows positive results from a Phase 3 trial in children aged 1 to 11 years with eosinophilic esophagitis (EoE).
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
October 23, 2023
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Capeserod
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
Details : Under the terms of the agreement, First Wave will receive from Sanofi an exclusive, global license for Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop for gastrointestinal (GI) indications.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 14, 2023
Lead Product(s) : Capeserod
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent® (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First and only investigational Phase 3 trial to show positive results in these young children; results follow recent approval of Dupixent (Dupilumab) in people with eosinophilic esophagitis aged 12 years and older who weigh at least 40 kilograms.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
July 14, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent 300 mg weekly, a fully human mAB that inhibits signaling of interleukin-4 and interleukin-13 pathways, significantly improved signs and symptoms of EoE at 24 weeks compared to placebo, including ability to swallow and reduction in eosinophil cou...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with eosinophilic esophagitis at 24 weeks compared to placebo in patients 12 years and older.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
February 26, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13. IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis w...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
October 25, 2021
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent’s unique mechanism of action simultaneously inhibits IL-4 and IL-13. Recent evidence further supports additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pul...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
November 06, 2020
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
